Bear in mind, the "CLAIM" made below came out right after...The
PHASE 3 Euphrates trial fininished...I MEAN right after ...like August 2016 to be "precise" (
AKA precision medicine for the bullboard )
How, WHO, WHY, .... $$$$ ... CTSO found the $15.23 USD level on a per share basis...achieving over
1/2 a BILLION USD as their market carp.....
Hmmmmmmmmmm . "I dunno either" ; - ) RE:RE: Is the CTSO "XL" product still going to eliminate PMX need?
BOLD statement ... AND "unchallenged"
Tell me........... mirror mirror on the wall ... "has the XL ever been used on a human at all"?
And the detail promptly delivered by our good friend the "economist" at an AGM .... "Indeed Doc, John is our friend"....but ultimately a BIG FAN of PMX and now a shareholder near as LARGE as you! Free dessert for ALL those on their way to the Merry Land.
INDEED ... let the "Beech Boys" continue to "work the bored" ...
A little too easy for the average bear to figger out....good thing...Peter Falk passed years ago! ; - )
In a head-to-head comparison with the leading endotoxin adsorber, Toraymyxin™ (Toray, Japan), CytoSorb-XL matched the level of endotoxin reduction in an in vitro plasma recirculation system on a comparable volume basis. CytoSorb-XL is expected to eliminate the need for stand-alone endotoxin specific filters by offering superior performance in the removal of not just endotoxin, but a much broader array of inflammatory mediators that drive uncontrolled deadly inflammation, organ failure, and death in sepsis